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Abstract Topical hemostatic agents can be used to treat
problematic bleedings in patients who undergo surgery.
Widely used are the collagen- and gelatin-based hemostats.
This study aimed to develop a fully synthetic, biodegrad-
able hemostatic agent to avoid exposure to animal antigens.
In this in vitro study the suitability of different newly
developed polyurethane-based foams as a hemostatic agent
has been evaluated and compared to commonly used
agents. An experimental in vitro test model was used in
which human blood ﬂowed through the test material. Dif-
ferent modiﬁed polyurethane foams were compared to
collagen and gelatin. The best coagulation was achieved
with collagen. The results of the polyurethane foam
improved signiﬁcantly by increasing the amount of poly-
ethylene glycol. Therefore, the increase of the PEG con-
centration seems a promising approach. Additional in vivo
studies will have to be implemented to assess the appli-
cation of polyurethane foam as a topical hemostatic agent.
1 Introduction
Topical hemostatic agents can be used to treat problematic
bleedings in patients who undergo surgery. The beneﬁts of
local hemostats include improving blood conservation by
reducing blood loss, shortening the time of hemostasis,
avoiding the adverse effects of systemic hemostatic drugs
and saving transfusion blood. Adverse effects can be for-
eign body reaction, infection, and granuloma formation [1].
Different types of hemostatic agents are available, each
with their own characteristics. The following characteris-
tics should be considered in search of an ideal hemostatic
material: ease of application and removal, bioresorption
potential, suturability, antigenicity, and tissue reactivity
effects [2]. The possibility to adjust absorbability and
ﬂexibility of the material would be a further advantage [3].
Some of the most widely used topical hemostatic agents
nowadays are collagen and gelatin which are animal-
derived products. Procoagulant substances like thrombin or
ﬁbrin are frequently added to these agents to increase their
hemostatic efﬁcacy [1].
However, the use of products from animal or human
origin has the potential risk of blood-borne pathogens and
immunization. Examples are Bovine Spongiform Enceph-
alopathy (BSE) and Creutzfeldt-Jakob disease. Bovine
collagen intended for collagen-based medical devices
should therefore not come from a country with known BSE
cases [1]. The use of bovine-derived components in
hemostats has resulted in a number of reports of immuni-
zation to bovine thrombin. The resulting antibodies can
cross-react with blood clotting factor V and lead to coag-
ulopathy [4].
A fully synthetic, biodegradable material with hemo-
static properties would prevent these potential risks.
Polyurethane (PU) with uniform hard segments composed
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ments of DL-lactide, e-caprolactone and polyethylene glycol
(PEG) is a synthetic biodegradable material with possible
hemostatic properties. Coagulation is initiated upon expo-
sure to a PU surface while the PEG makes the material
more hydrophilic which increases the attraction of platelets
[5]. In a previous in vivo study the good biocompatibility
of a comparable PU without PEG moieties has been
demonstrated [6].
It is not known whether PU foam has hemostatic prop-
erties or can be modiﬁed to a hemostatic agent. We ques-
tioned in this in vitro study if PU foam can achieve similar
hemostatic properties as commercially available products.
Therefore, PU foams were compared to an absorbable
collagen hemostat (Novacol) and an absorbable gelatin
sponge (Spongostan). Different modiﬁcations were applied
to the PU foam to test whether they might increase its
hemostatic efﬁcacy. The PU foam was enriched with
rFVIIa (recombinant factor VIIa), phospholipids, ADP
(adenosine diphosphate) and thrombin. Factor VII is one of
the central proteins in the coagulation cascade. When
factor VIIa forms a complex with tissue factor (TF) the
extrinsic pathway of the coagulation cascade is initiated
[7]. Phospholipids greatly enhance the binding of factor
VIIa to TF. ADP interacts with platelets, leading to further
platelet activation [8]. Thrombin is a coagulation protein
that has many effects in the coagulation cascade including
platelet activation and the conversion of ﬁbrinogen into
ﬁbrin [9]. Furthermore, some of the PU foams were treated
with ‘plasma glow discharge’ which creates a more
hydrophilic foam with enhanced platelet binding and
activation [10].
An experimental in vitro test model was used in which
fresh human whole blood ﬂowed through the test materials.
This test model was based on the Thrombostat 4000

which is used to measure in vitro bleeding time and volume
[11].
2 Materials and methods
2.1 Materials
In this study tests have been performed with PU, Novacol
(absorbable collagen hemostat; Bioprof BV, Moerkapelle,
the Netherlands) and Spongostan (absorbable gelatin
sponge; Johnson & Johnson, Skipton, UK).
The used PU is a block-copolymer composed of ure-
thane hard segments and co-polyether-ester soft segments.
This was done to achieve rapid degradation. The soft
segments consisted of 50% DL-lactide and 50% e-capro-
lactone. In a ﬁrst PU foam formulation, PEG 1000 was
used as initiator for the soft segments synthesis, and in a
second one PEG 20.000 was added in a ratio of 3–1 to
prepare a blend. The urethane segments were synthesized
with 1,4-butanediisocyanate (BDI) and 1,4-butanediol
(BDO). They had a uniform length of 5 urethane moieties,
which resulted in a PU with BDI–BDO–BDI–BDO–BDI
urethane segments in the polymer. The PU was then dis-
solved in 1,4-dioxane. After dissolving, the solution was
poured into a mold and cooled down to -18C. The
solution was freeze-dried at 3 mbar to remove the 1,4-
dioxane crystals, resulting in an highly porous foam with a
porosity of 97% and an overall PEG-content of 40 wt%.
Overall porosity was calculated after determining the
weight and dimensions of the foams.
The second PU foam formulation created a much more
hydrophilic foam due to the increased PEG concentration.
This foam had a porosity of 97% and an overall PEG-
content of 55 wt%.
The foams were processed to round slices with a
diameter of 4 mm and a thickness of 2 mm. The foams
were ultimately sterilized using ethylene oxide (EtO). The
polymers and foams were manufactured by Polyganics BV
(Groningen, The Netherlands). The collagen and gelatin
materials were, like the PU foams, processed to round
slices with a diameter of 4 mm and a thickness of 2 mm.
After the sterilisation process 145 foams were modiﬁed
to potentially increase their hemostatic efﬁcacy. This was
done by adding 10 ll of a procoagulant substance or sur-
face treatment. In Table 1 an overview is presented of the
added procoagulant substances and surface treatment.
2.1.1 Procoagulant substances
Prior to adding the substances, the PU foams were treated
for 15 min with 5 ll of a 15% glutaraldehyde solution to
increase the attachment of the substances. Treatment with
glutaraldehyde is a procedure which can be employed to
stabilize the binding of enzymes [12]. The excess of glu-
taraldehyde was washed away with copious amounts of
phosphate buffer solution (pH 7.4) and ultimately with
Table 1 Overview of the added substances to the PU foams
PEG concentration
of PU foam (wt%)
Added substance
or treatment
Number
of treated
foams
40 Recombinant FVIIa (0.1 mg/ml) 30
40 Phospholipid solution (100 mg/ml) 20
40 Adenosine diphosphate (ADP)
(0.085 mg/ml)
20
40 Bovine thrombin (100 NIH U/ml) 10
55 Recombinant FVIIa (0.1 mg/ml) 25
40 Saline (0.9% NaCl) 10
40 Plasma glow discharge 30
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123ultra-pure water. The substances were immediately applied
to the foams 1 h before testing using a volumetric pipette.
2.1.2 Surface treatment
Glow discharge treatment was performed at 50 W during
5 min at both sides. Vacuum was achieved by a dual trap
vacuum pump and was always lower than 1800 Pa prior to
argon (99.996%, Hoekloos Nederland BV., The Nether-
lands) inlet. The argon pressure during plasma treatment
was 500 Pa. After glow discharge, the reactor chamber was
ventilated with ambient air. The surface characterisation of
the treated PU foams was analysed by X-ray photoemission
spectroscopy. This showed an increase of oxygen and
nitrogen which resulted in a lower contact angle and thus
higher hydrophilicity.
2.2 Methods
2.2.1 Blood preparation
The study was approved by the ethics committee of the
University Medical Center Groningen, the Netherlands.
The blood that was used for this study was obtained from
10 healthy adult volunteers. Exclusion criteria were a
known disease or use of drugs that could have inﬂuence on
blood coagulation. Each volunteer donated 30 ml of blood
which was tested for normal trombocyte count. To prevent
the blood from instant clotting, heparin was added to a
concentration of 1.5 IU of heparin per ml blood. The blood
was then divided over 30 microcentrifuge tubes, one ml per
tube and kept at room temperature. This way 30 tests could
be performed from each blood donation, the tests were
ﬁnished within 2 h after the blood was obtained. Each
session the materials were tested in a different order to
level the inﬂuence of time after the blood donation. A
series of tests was performed without material as a control
group. Recombinant tissue factor (rTF) in a concentration
of 5 pM was added to each ml of blood to resemble the
wound situation in vivo. This was necessary because no
detectible concentrations of active TF are present in the
blood of healthy donors [13]. While in a wound situation,
extravascular TF is exposed to the blood and binds plasma
factor VIIa [7].
2.2.2 Test device
An experimental in vitro test model was used which was
based on the Thrombostat 4000
 (Von der Goltz, Seeon,
Germany). This device was used because of the possibility
to insert different test materials in an existing model for
measuring hemostasis in vitro. In this model blood ﬂowed
through the ﬁxated test materials with a constant pressure
of -40 mbar. Suction of the blood was performed through
a needle with a diameter of 200 lm to create shear stress
(Fig. 1). The shear stress was necessary to mimic capillary
bleeding which is an important platelet activator in vivo.
The thrombostat calculated the amount of blood ﬂow
through the test material over a period of 90 s. As a
derivative for the extent of coagulation the blood ﬂow
deceleration was determined. This was calculated out of
the blood volume that had passed the test material after 30,
60 and 90 s. The volume after 30 s was used to obtain the
velocity of blood ﬂow at 30 s. This was done by dividing
the volume after 30 s by 30 and deﬁned as initial velocity
(Vi)i nll/s. The ﬁnal velocity (Vf)i nll/s was calculated by
dividing the volume that had ﬂowed between 60 and 90 s
by 30. The deceleration (d)i nll/s
2 could be calculated by
dividing the difference between initial and ﬁnal velocity
by the time interval in seconds (t) using the formula
d = (Vf-Vi)/t.
2.2.3 Thrombin-antithrombin complexes (TAT)
The extent of thrombin generation in vitro was determined
by measuring thrombin-antithrombin complexes (TAT) in
two of the blood samples. The measurement was performed
30 min after venous blood collection. In two of the blood
samples that had ﬂowed through the PU foam (55% PEG)
with and without rFVIIa the amount of TAT was also
determined. After the experiment 500 ll of blood was
collected and added to 50 ll EDTA-solution (0.1 mol/ml)
to prevent further generation of thrombin. The blood
sample was then centrifuged, and 200 ll of the superna-
tants were collected and stored at -20C until further
analysis. Enzyme-linked immunosorbent assay (Cedarlane
Fig. 1 In vitro test model. Suction of human whole blood was
performed with a constant pressure of -40 mbar. Ø, diameter
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123Ltd., Burlington, Ont., Canada) was employed for mea-
surement of the TAT complexes.
2.2.4 Statistical analysis
Statistical analysis was performed using SPSS 16.0. Group
differences were calculated by the Mann–Whitney-U-test.
P values less than 0.05 were considered statistically
signiﬁcant.
3 Results
The mean decelerations and their standard deviations were
calculated per material and are presented in order of efﬁ-
cacy in Table 2.
For a clear overview the mean decelerations are also
presented in a boxplot (Fig. 2).
The best results were achieved with collagen which per-
formed signiﬁcantly better than the other materials
(P\0.001). The second best results were achieved with
gelatin which performed signiﬁcantly better than the control
group without material and than the PU foams with 40%
PEG, with or without rFVIIa (P\0.001). The PU foams
with40%PEGshowednosigniﬁcantdifferencecomparedto
the control group without material. The PU foams with 55%
PEG showed a signiﬁcantly higher deceleration than the PU
foams with 40% PEG (P\0.001). Again the addition of
rFVIIa to the foams gave no improvement of the results. No
signiﬁcant difference was observed between the PU foams
with 55% PEG and gelatin.
The results of the modiﬁed PU foams (40% PEG) are
also presented in a boxplot (Fig. 3).
In the group with the modiﬁed PU foams, collagen again
performed signiﬁcantly better than the other materials
(P\0.001). The PU foams which were treated with
‘plasma glow discharge’ showed a signiﬁcantly higher
deceleration than the tests without material (P\0.02). The
PU foams which were enriched with phospholipids, aden-
osine diphosphate, saline and thrombin showed no signif-
icantly different results from the tests without material.
The blood took an average time of 12.1 s (SD: 0.83) to
reach the material after suction was started. When the
blood took more than 14 s to reach the material the results
from these tests were excluded. This was the case in 20 out
of the 305 tests.
3.1 Thrombin-antithrombin complexes (TAT)
Three duplo measurements were performed to assess the
amount of TAT complexes before and after ﬂow through
the PU foam (55% PEG) with and without rFVIIa. Results
of this measurement are presented in Table 3.
The plasma concentration of TAT complexes in vitro
30 min after venous blood collection is above the normal
range (1.0–4.1 lg/l) in vivo [14]. Approximately the same
concentration of TAT was found in the blood samples that
Table 2 Mean deceleration and standard deviation of the different
materials
Material Mean deceleration
(ll/s
2)
Standard
deviation
Collagen 0.036 0.022
Gelatin 0.021 0.016
PU (55% PEG) 0.015 0.007
PU (55% PEG) ? rFVIIa 0.015 0.006
PU ? glow discharge 0.012 0.011
PU ? thrombin 0.009 0.011
PU ? saline 0.008 0.005
PU (40% PEG) ? rFVIIa 0.004 0.011
PU (40% PEG) 0.002 0.010
No material -0.001 0.009
PU ? ADP -0.002 0.015
PU ? PL -0.003 0.015
PU polyurethane; PEG polyethylene glycol; rFVIIa recombinant
factor VIIa; ADP adenosine diphosphate; PL phospholipids
Fig. 2 Schematic representation of decelerations for the different test
materials. Thenumberoftested samples (n)is noted.PU polyurethane;
PEG polyethylene glycol; rFVIIa recombinant factor VIIa. For each
group,thelineinthemiddleoftheboxrepresentsthemedian.Thelower
andtheupperedgesoftheboxarethe1stand3rdquartile,respectively.
The fences are drawn to the nearest value not exceeding 1.5
(interquartile range). *P\0.001 compared with control group (No
Material)
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123had ﬂowed through the PU foam (55% PEG) without
rFVIIa. The blood samples that had ﬂowed through the PU
foam (55% PEG) with rFVIIa showed a higher concen-
tration of TAT complexes.
4 Discussion
An experimental in vitro test model was used to compare
the synthetic PU foam to commercially available hemo-
static materials. Additional rTF was added to the blood to
more closely resemble the wound situation in vivo. Dif-
ferent modiﬁcations have been applied to the PU foam to
increase its hemostatic efﬁcacy. The addition of rFVIIa to
the PU foam did not inﬂuence the results. The effect of
intravenous rFVIIa has been proven to reduce blood loss in
severe blunt trauma patients in a multicenter randomized
controlled trial [15]. In a study in rats the local use of a
microporous polysaccharide hemosphere (MPH) in com-
bination with freeze-dried rFVIIa signiﬁcantly improved
hemostasis [16]. The failure of rFVIIa to improve the
results of PU foam in this study could indicate that the
extrinsic pathway of the coagulation cascade was not
adequately activated in the current test model. The
extrinsic pathway is initiated by the combination of TF and
FVIIa and clotting time with normal protein concentrations
is approximately 8.6 s [17]. In the used test model the
blood ﬂowed through the material during 90 s. Under the
inﬂuence of heparin which inhibits thrombin and factor Xa
this time period might have been too short [18]. Another
explanation could be that the applied rFVIIa was ﬂushed
out of the PU foam by the blood and therefore did not
contribute to the coagulation. The same could be true for
the other applied substances which gave no improved
blood coagulation. Another explanation is that the com-
plexity of the coagulation cascade might not be adequately
resembled in vitro. This process was further complicated
by the necessary addition of heparin which inhibits the
coagulation cascade [18].
The PU foams which have been enriched with phos-
pholipids, adenosine diphosphate and thrombin gave no
improved results. With the addition of thrombin to a local
hemostatic agent good results have been achieved in in
vivo studies [19, 20].
The good results of collagen in this study could be
explained by its action mechanism which is based pre-
dominantly on platelet aggregation. Collagen-based
hemostats attract platelets when they get in contact with
blood. The platelets adhere to collagen ﬁbrils and
degranulate, thereby triggering platelet aggregation [21].
The improved results of PU foam after modiﬁcation of
the PEG concentration could indicate that this enhanced the
attraction of platelets. In a study by Lee et al. [22] the
platelet adhesion to a PU surface increased slightly when
short PEG chains were added whereas long PEG chains
prevented platelet adhesion. The absorbable properties of
PEG might contribute to its hemostatic effect by concen-
tration of the endogenous coagulation factors and platelets.
The effect of cellulose- and polysaccharide-based hemo-
stats is based partly on this mechanism [17, 23].
To analyse the inﬂuence of adding ﬂuids to the foam
some PU foams have been enriched with saline. As
expected these foams gave no improved results compared
to the PU foam without modiﬁcations.
The treatment of PU foams with glow discharge led to
signiﬁcantly better results. This should be contributed to
the electrostatic charge at the membrane surface which
creates a more hydrophilic material. By increasing the
Fig. 3 Schematic representation of decelerations for the different
modiﬁed PU foams (40% PEG). The number of tested samples (n)i s
noted. The results of collagen have been added to this boxplot as a
reference. PU polyurethane; PL phospholipids; ADP adenosine
diphosphate; GD glow discharge. For each group, the line in the
middle of the box represents the median. The lower and the upper
edges of the box are the 1st and 3rd quartile, respectively. The fences
are drawn to the nearest value not exceeding 1.5 (interquartile range).
*P\0.001 compared with control group (No Material). **P\0.05
compared with control group (No Material)
Table 3 Thrombin-antithrombin complexes in the different blood
samples
Blood sample TAT (mg/L) Standard deviation
Before testing 1.38 0.06
After PU 1.36 0.07
After PU ? rFVIIa 2.40 0.12
PU polyurethane; rFVIIa recombinant factor VIIa
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more platelet adhesion and activation of the clotting sys-
tem. In 20 out of the 305 tests the blood took more than
14 s to reach the material and therefore the results from
these tests were excluded. The delay in blood ﬂow could be
due to obstruction of the 200 lm needle.
An advantage of our in vitro model was the easy way to
test the efﬁcacy of a large number of modiﬁcations in
multifold experiments with human blood. A few drawbacks
of the in vitro model were also demonstrated. Generation
of thrombin after collection of blood can lead to activation
of platelets and subsequent loss of response to agonists
[24]. The addition of heparin to the blood does not com-
pletely block the generation of thrombin in vitro [25]. This
is supported by the results of the TAT generation test. The
TAT concentration in blood before contact with any he-
mostatic agent showed a 1000-fold increase compared to
normal blood. The lowering blood temperature might also
have contributed to a diminished platelet function [26].
In this in vitro coagulation study the best results were
achieved with collagen. Increase of the PEG concentration
improved the results of PU foam signiﬁcantly and seems a
promising approach. There were no signiﬁcant differences
between this modiﬁed PU foam and gelatin. The results of
collagen,however,couldnotbematched.Additionalinvivo
studieswillhavetobeimplementedtoassesstheapplication
of polyurethane foam as a local hemostatic agent.
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